Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804403 | 0.86 | POLB (0.47) | PDE2ALMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1197498 | 0.83 | LMNA (0.68) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL173737 | 0.80 | POLB (0.69) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL18096242 | 0.80 | LMNA (0.49) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL5643904 | 0.80 | GAA (0.49) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL12821489 | 0.80 | LMNA (0.49) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL10150650 | 0.78 | MAPT (0.53) | SMN1; SMN2KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL10150643 | 0.78 | LMNA (0.47) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL22632964 | 0.76 | CYP1A2 (0.48) | LMNASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL10150645 | 0.75 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9562055-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | PDE2A 877/4885LMNA 2916/4885SMN1; SMN2 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.